Mereo Biopharma Stock Price, News & Analysis

Mereo BioPharma Group plc (NASDAQ: MREO) will host a virtual R&D day on November 24, 2020, to discuss its key pipeline programs. The event will focus on etigilimab (Anti-TIGIT) for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease. Key opinion leaders from renowned institutions will present insights into the etigilimab development program. A live audio webcast will be available on the company’s website and an archived replay will follow. This initiative aims to enhance stakeholder understanding of Mereo's innovative therapeutic developments.

Mereo BioPharma Group, a clinical stage biopharmaceutical company, announced that CEO Dr. Denise Scots-Knight will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 am ET. Investors can access a live audio webcast via the company’s website, with an archived version available for two weeks after the event. Mereo focuses on oncology and rare diseases, with products like etigilimab and setrusumab currently in various clinical trials. Forward-looking statements in the announcement caution investors about potential risks and uncertainties.

Mereo BioPharma Group plc (NASDAQ: MREO) announces the appointment of Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President of Regulatory Affairs. Fox, a CPA with over 18 years of experience, replaces interim CFO Michael Wyzga, while Petersen brings 25 years of regulatory expertise in biopharmaceuticals. Their appointments come as Mereo anticipates significant milestones in its pipeline, including a Phase 1b/2 study for its anti-TIGIT antibody, etigilimab, set to begin soon. Both bring valuable skills to strengthen Mereo's leadership.

Mereo BioPharma Group plc (NASDAQ: MREO) announced FDA clearance for its IND application to initiate a Phase 1b/2 study of etigilimab, a novel anti-TIGIT monoclonal antibody, in Q4 2020. The study will evaluate etigilimab with anti-PD-1 in 100 patients across various tumor types. Results from prior studies indicated no dose-limiting toxicities, with some patients achieving partial responses. Mereo plans a virtual R&D day in November 2020 to discuss the etigilimab program and its rare disease pipeline.

Mereo BioPharma Group plc (NASDAQ: MREO) reported its interim financial results for the first half of 2020, highlighting a successful $70 million PIPE financing, enhancing its cash resources to £56.8 million. The company is on track to start its Phase 1b/2 study for etigilimab (Anti-TIGIT) in Q4 2020 and has resumed enrollment in the Phase 2 study of alvelestat for Alpha-1 Antitrypsin Deficiency. Recent advancements include initiating a Phase 1b/2 clinical trial for alvelestat in COVID-19 patients and ongoing partnering discussions for its clinical-stage programs.

Mereo BioPharma Group plc (NASDAQ: MREO) reported interim financial results for the six months ended June 30, 2020, focusing on oncology and rare diseases. The company successfully completed a $70 million PIPE financing and has cash resources of £56.8 million, ensuring a runway into early 2022. They aim to initiate a Phase 1b/2 study of etigilimab in Q4 2020 and have resumed enrollment for alvelestat's Phase 2 study in Alpha-1 Antitrypsin Deficiency. Partnering discussions for setrusumab and other programs are ongoing.

Mereo BioPharma Group has received Rare Pediatric Disease designation from the FDA for its treatment setrusumab, aimed at osteogenesis imperfecta (OI), a rare genetic disorder without approved therapies. Setrusumab is a monoclonal antibody that inhibits sclerostin to promote bone formation. In clinical studies, it showed promising results in bone-building and fracture reduction. If a Biologics License Application is approved, Mereo may obtain a priority review voucher from the FDA, potentially facilitating future drug applications.

Mereo BioPharma Group plc (NASDAQ: MREO) will announce its interim financial results for the six months ended June 30, 2020, on September 29, 2020, at 7:00 a.m. EDT. Following this, a conference call will occur at 8:00 a.m. EDT to discuss the results and corporate updates. Mereo focuses on developing therapeutics for oncology and rare diseases, with notable candidates like etigilimab and setrusumab nearing advanced clinical trials. Investors can access the live and archived call via the company’s website.

Mereo BioPharma (NASDAQ: MREO, AIM: MPH) announced the start of a Phase 1b/2 clinical trial for alvelestat, targeting moderate to severe COVID-19 respiratory disease. The trial, led by Dr. J. Michael Wells at the University of Alabama, aims to assess the safety and efficacy of alvelestat, a novel oral small molecule that inhibits neutrophil elastase (NE). Approximately 15 patients will be randomized to receive alvelestat or placebo. Primary endpoints focus on safety and tolerability by day 10, with further evaluations of biomarkers and clinical outcomes.